Porcilis PCV

国家: 欧盟

语言: 英文

来源: EMA (European Medicines Agency)

现在购买

资料单张 资料单张 (PIL)
06-09-2021
产品特点 产品特点 (SPC)
06-09-2021
公众评估报告 公众评估报告 (PAR)
15-01-2009

有效成分:

porcine circovirus type 2 ORF2 subunit antigen

可用日期:

Intervet International BV

ATC代码:

QI09AA07

INN(国际名称):

adjuvanted inactivated vaccine against porcine circovirus

治疗组:

Pigs

治疗领域:

Immunologicals for suidae

疗效迹象:

For the active immunisation of pigs to reduce the virus load in blood and lymphoid tissues and to reduce weight loss associated with porcine-circovirus-type-2 infection occurring during the fattening period.Onset of immunity: 2 weeksDuration of immunity: 22 weeks

產品總結:

Revision: 7

授权状态:

Authorised

授权日期:

2009-01-12

资料单张

                                16
B. PACKAGE LEAFLET
17
PACKAGE LEAFLET:
Porcilis PCV emulsion for injection for pigs
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Intervet International BV
Wim de Körverstraat 35
5831 AN Boxmeer
The NETHERLANDS
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis PCV emulsion for injection for pigs
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENTS
Each dose of 2 ml contains:
Porcine circovirus type 2 ORF2 subunit antigen: ≥ 3720 Antigenic
Units as determined in the in vitro
potency test (AlphaLISA)
Adjuvants:
25 mg dl-α-tocopheryl acetate
346 mg light liquid paraffin.
Emulsion for injection. Opalescent white, with brown resuspendable
sediment.
4.
INDICATION(S)
For the active immunisation of pigs to reduce the virus load in blood
and lymphoid tissues and to
reduce mortality and weight loss associated with PCV2 infection
occurring during the fattening period.
Onset of immunity:
2 weeks
Duration of immunity:
22 weeks.
5.
CONTRAINDICATIONS
None
6.
ADVERSE REACTIONS
In laboratory studies and field trials:
Transient local reactions at the injection site were very commonly
observed after vaccination mainly
in the form of a hard, warm and sometimes painful swelling (diameter
up to 10 cm). These reactions
resolve spontaneously over a period of approximately 14–21 days
without any major consequence on
the general health status of the animals. Immediate systemic
hypersensitivity-like reactions were
commonly observed after vaccination, resulting in minor neurological
symptoms such as tremors
and/or excitation, which normally resolve within minutes without
requiring treatment. A transient
increase in body temperature, normally not exceeding 1 °C, was very
commonly observed until 2 days
18
after vaccination. In individual animals, an increase of rectal
temperature of 2.5 °C lasting less than
24 hours was uncommonly observed.
I
                                
                                阅读完整的文件
                                
                            

产品特点

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Porcilis PCV emulsion for injection for pigs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose of 2 ml contains:
Active substance:
Porcine circovirus type 2 ORF2 subunit antigen: ≥3720 AU*
* Antigenic Units as determined in the in vitro potency test
(AlphaLISA).
Adjuvants:
Dl-α-tocopheryl acetate
25 mg
Light liquid paraffin
346 mg
Excipients:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Emulsion for injection.
Opalescent white, with brown resuspendable sediment.
4.
CLINICAL PARTICULARS
4.1
Target species
Pigs
4.2
Indications for use, specifying the target species
For the active immunisation of pigs to reduce the virus load in blood
and lymphoid tissues and to
reduce mortality and weight loss associated with PCV2 infection
occurring during the fattening period.
Onset of immunity:
2 weeks
Duration of immunity:
22 weeks.
4.3
Contraindications
None
4.4
Special warnings for each target species
From the data provided, it can be concluded that a single dose regimen
of vaccination breaks through
up to medium levels and double dose regimen through medium to high
levels of maternally derived
antibodies in piglets.
No data are available on the use of the vaccine in breeding boars.
4.5
Special precautions for use
Special precautions for use in animals
3
Vaccinate only healthy animals.
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
To the user:
This veterinary medicinal product contains mineral oil. Accidental
injection/self-injection may result
in severe pain and swelling, particularly if injected into a joint or
finger, and, in rare cases, could result
in the loss of the affected finger if prompt medical attention is not
given. If you are accidentally
injected with this product, seek prompt medical advice even if only a
very small amount is injected
and take the package insert with you. If pain persists for more than
12 hours after medical
exam
                                
                                阅读完整的文件
                                
                            

其他语言的文件

资料单张 资料单张 保加利亚文 06-09-2021
产品特点 产品特点 保加利亚文 06-09-2021
公众评估报告 公众评估报告 保加利亚文 15-01-2009
资料单张 资料单张 西班牙文 06-09-2021
产品特点 产品特点 西班牙文 06-09-2021
公众评估报告 公众评估报告 西班牙文 15-01-2009
资料单张 资料单张 捷克文 06-09-2021
产品特点 产品特点 捷克文 06-09-2021
公众评估报告 公众评估报告 捷克文 15-01-2009
资料单张 资料单张 丹麦文 06-09-2021
产品特点 产品特点 丹麦文 06-09-2021
公众评估报告 公众评估报告 丹麦文 15-01-2009
资料单张 资料单张 德文 06-09-2021
产品特点 产品特点 德文 06-09-2021
公众评估报告 公众评估报告 德文 15-01-2009
资料单张 资料单张 爱沙尼亚文 06-09-2021
产品特点 产品特点 爱沙尼亚文 06-09-2021
公众评估报告 公众评估报告 爱沙尼亚文 15-01-2009
资料单张 资料单张 希腊文 06-09-2021
产品特点 产品特点 希腊文 06-09-2021
公众评估报告 公众评估报告 希腊文 15-01-2009
资料单张 资料单张 法文 06-09-2021
产品特点 产品特点 法文 06-09-2021
公众评估报告 公众评估报告 法文 15-01-2009
资料单张 资料单张 意大利文 06-09-2021
产品特点 产品特点 意大利文 06-09-2021
公众评估报告 公众评估报告 意大利文 15-01-2009
资料单张 资料单张 拉脱维亚文 06-09-2021
产品特点 产品特点 拉脱维亚文 06-09-2021
公众评估报告 公众评估报告 拉脱维亚文 15-01-2009
资料单张 资料单张 立陶宛文 06-09-2021
产品特点 产品特点 立陶宛文 06-09-2021
公众评估报告 公众评估报告 立陶宛文 15-01-2009
资料单张 资料单张 匈牙利文 06-09-2021
产品特点 产品特点 匈牙利文 06-09-2021
公众评估报告 公众评估报告 匈牙利文 15-01-2009
资料单张 资料单张 马耳他文 06-09-2021
产品特点 产品特点 马耳他文 06-09-2021
公众评估报告 公众评估报告 马耳他文 15-01-2009
资料单张 资料单张 荷兰文 06-09-2021
产品特点 产品特点 荷兰文 06-09-2021
公众评估报告 公众评估报告 荷兰文 15-01-2009
资料单张 资料单张 波兰文 06-09-2021
产品特点 产品特点 波兰文 06-09-2021
公众评估报告 公众评估报告 波兰文 15-01-2009
资料单张 资料单张 葡萄牙文 06-09-2021
产品特点 产品特点 葡萄牙文 06-09-2021
公众评估报告 公众评估报告 葡萄牙文 15-01-2009
资料单张 资料单张 罗马尼亚文 06-09-2021
产品特点 产品特点 罗马尼亚文 06-09-2021
公众评估报告 公众评估报告 罗马尼亚文 15-01-2009
资料单张 资料单张 斯洛伐克文 06-09-2021
产品特点 产品特点 斯洛伐克文 06-09-2021
公众评估报告 公众评估报告 斯洛伐克文 15-01-2009
资料单张 资料单张 斯洛文尼亚文 06-09-2021
产品特点 产品特点 斯洛文尼亚文 06-09-2021
公众评估报告 公众评估报告 斯洛文尼亚文 15-01-2009
资料单张 资料单张 芬兰文 06-09-2021
产品特点 产品特点 芬兰文 06-09-2021
公众评估报告 公众评估报告 芬兰文 15-01-2009
资料单张 资料单张 瑞典文 06-09-2021
产品特点 产品特点 瑞典文 06-09-2021
公众评估报告 公众评估报告 瑞典文 15-01-2009
资料单张 资料单张 挪威文 06-09-2021
产品特点 产品特点 挪威文 06-09-2021
资料单张 资料单张 冰岛文 06-09-2021
产品特点 产品特点 冰岛文 06-09-2021
资料单张 资料单张 克罗地亚文 06-09-2021
产品特点 产品特点 克罗地亚文 06-09-2021

查看文件历史